|
U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Cancer Institute (NCI) <https://www.cancer.gov/> For Immediate Release: Thursday, July 14, 2022 Media Contact: NCI Press Office, 240-760-6600, <e-mail:NCIPressOfficers@xxxxxxxxxxxx> MEDIA ADVISORY INTERFERON TREATMENT MAY REDUCE SEVERITY OF COVID-19 IN PEOPLE WITH CERTAIN GENETIC FACTORS WHAT Researchers from the National Cancer Institute, part of the National Institutes of Health, and their collaborators have discovered that people of European and African ancestries who were hospitalized for COVID-19 are more likely to carry
a particular combination of genetic variants in a gene known as OAS1 than patients with mild disease who were not hospitalized. People with this combination of genetic variants also remain positive for SARS-CoV-2 infection longer. However, interferon treatment
may reduce the severity of COVID-19 in people with these genetic factors. Interferons are a type of protein that can help the body’s immune system fight infection and other diseases, such as cancer.
The study appears July 14 in Nature Genetics. These findings build on previous studies that have suggested that genetic factors, such as genetic variants affecting OAS antiviral proteins that facilitate the detection and breakdown of the SARS-CoV-2 virus, may influence the risk of
SARS-CoV-2 infection. The NCI researchers and their collaborators found that treatment of cells with an interferon decreased the viral load of SARS-CoV-2. The researchers also analyzed data from a clinical trial in which patients with COVID-19 who were not hospitalized
were treated with the recombinant interferon pegIFN-λ1 and found that treatment improved viral clearance in all patients; those with the OAS1 risk variants benefitted the most. The results suggest that interferon treatment may improve COVID-19 outcomes and
specifically in patients with certain OAS1 genetic variants who have impaired ability to clear infection. WHO Ludmila Prokunina-Olsson, Ph.D., and Oscar Florez-Vargas, Ph.D., Division of Cancer Epidemiology and Genetics, National Cancer Institute REFERENCE “Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries.” July 14. Nature Genetics. DOI: 10.1038/s41588-022-01113-z.
About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of people with cancer. NCI supports a wide range of cancer research
and training extramurally through grants and contracts. NCI’s intramural research program conducts innovative, transdisciplinary basic, translational, clinical, and epidemiological research on the causes of cancer, avenues for prevention, risk prediction,
early detection, and treatment, including research at the NIH Clinical Center—the world’s largest research hospital. Learn more about NCI’s intramural research from the Center for Cancer Research and the Division of Cancer Epidemiology and Genetics. For more
information about cancer, please visit the NCI website at cancer.gov or call NCI’s contact center at 1-800-4-CANCER (1-800-422-6237). About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting
and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <https://www.nih.gov>. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at: https://www.nih.gov/news-events/news-releases/interferon-treatment-may-reduce-severity-covid-19-people-certain-genetic-factors> To subscribe (or unsubscribe) from NIH News Release mailings, go to <http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>. If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>. |
